Last reviewed · How we verify
NCT07230249: TELEGRAM-MI
Telegram Messenger Support for Smoking Cessation After Heart Attack
NA trial testing Telegram-based Smoking Cessation Support in Myocardial Infarction (MI) in 142 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | ITMO University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 142 |
| Start date | 1 May 2026 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Telegram-based Smoking Cessation Support
- Standard Care (in control arm) — full drug profile →
Conditions studied
- Myocardial Infarction (MI) — all drugs for Myocardial Infarction (MI) →
- Tobacco Use — all drugs for Tobacco Use →
- Smoking Cessation — all drugs for Smoking Cessation →
Sponsor
ITMO University
Who can join
18 and older, any sex, with Myocardial Infarction (MI) or Tobacco Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI). Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either: * INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support. * CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content. The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics. This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07230249
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myocardial Infarction (MI)
Currently open trials in the same condition.
- NCT07052799 — Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/o · Phase 3 · recruiting
- NCT07320625 — Efficacy of Montelukast on STEMl Patients · Phase 3 · recruiting
- NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
- NCT07137936 — Cardiac Magnetic Resonance - PROgnostic HEart Scar for Sudden Cardiac Death Prediction StudY · recruiting
- NCT07243769 — A Pilot Randomized Controlled Trial Comparing Core Exercise, Aerobic Exercise, and Combined Exercise in Patients Undergo · NA · recruiting
Other ITMO University trials
Trials by the same sponsor.
- NCT06131463 — Anxiety Associated With the Use of the Electrocardiogram Function in Smart Watches · NA · completed
- NCT06122857 — Trends of Cancer Incidence and Mortality in Russia · active not recruiting
- NCT06152315 — Mitral Splay Sign, Its Mechanism and Association With Severity of Regurgitation · unknown
- NCT05394441 — Health and Quality of Life of ITMO University's Students, Faculty and Staff · completed
- NCT06151132 — Treatment of Atrial Fibrillation in the Community Settings · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07230249 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ITMO University
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07230249.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing